Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TolaSure in Severe EBS
NCT05062070Phase 1Completed
- Sponsor
- BioMendics
- Start
- May 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TolaSure Vehicle Gel in epidermolysis bullosa simplex (EBS) (2 arms), sponsored by BioMendics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 10 weeks. Started May 2022; status: completed.
02
Drugs
TolaSure Vehicle Gel
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on NCT05062070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062070.